Alpha- Antitrypsin Deficiency: Comprehensive Global Clinical Trials Analytics H2 2018

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Alpha- Antitrypsin Deficiency: Comprehensive Global Clinical Trials Analytics H2 2018

  • 131 Pages | Published On: 12-Apr-18 | Format:PDF | Last Updated: Updation in process
  • “GervanoRA’s Clinical trials report “Alpha- Antitrypsin Deficiency: Comprehensive Global Clinical Trials Analytics H2 2018” provides an in-depth analysis of the overall clinical trials for Alpha- Antitrypsin Deficiency. The report caters information related to the global clinical trials with respect to their Phase, Trial Status, Intervention, Trial type and Endpoint status. Our report exclusively focuses on providing insights and competitive opportunities based on Biomarker or target receptor, Drug Class and Mechanism of Action to aid in understanding the upcoming newer research trends in the field of Alpha- Antitrypsin Deficiency drug discovery. The report offers coverage of Alpha- Antitrypsin Deficiency clinical trials by region and average enrollment by country. Country based analytics are provided according to the Top 5 Clinical trial sites globally and the emerging countries supporting with a platform to conduct clinical trials effectively. Analytics are also provided for the subjects enrolled over a period of time, Alpha- Antitrypsin Deficiency clinical trials by sponsor type and the top companies involved in the R&D of Alpha- Antitrypsin Deficiency drug development. In addition, the report gives a brief overview on the major drugs undergoing trials and the recent advancements observed in the Alpha- Antitrypsin Deficiency clinical trials.

  • TABLE OF CONTENTS
    1. INTRODUCTION
    1.1. REPORT DESCRIPTION
    1.2. RESEARCH METHODOLOGY
    1.3. UPCOMING AND OTHER AVAILABLE REPORTS
    1.4. ABOUT US: GERVANORA DATA SERVICES
    2. GERVANORA CLINICAL TRIALS REPORT COVERAGE
    3. EXECUTIVE SUMMARY
    3.1 MAJOR FINDINGS
    3.2 TRIALS EXPECTED TO COMPLETE IN 5 YEARS
    4. ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS BASED ON BIOMARKERS OR TARGET RECEPTOR
    4.1 PHASE 3 CLINICAL TRIALS ANALYTICS BASED ON BIOMARKERS OR TARGET RECEPTOR
    4.2 PHASE 2 CLINICAL TRIALS ANALYTICS BASED ON BIOMARKERS OR TARGET RECEPTOR
    4.3 PHASE 1 CLINICAL TRIALS ANALYTICS BASED ON BIOMARKERS OR TARGET RECEPTOR
    5. ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS BASED ON DRUG CLASS
    5.1 PHASE 3 CLINICAL TRIALS ANALYTICS BASED ON DRUG CLASS
    5.2 PHASE 2 CLINICAL TRIALS ANALYTICS BASED ON DRUG CLASS
    5.3 PHASE 1 CLINICAL TRIALS ANALYTICS BASED ON DRUG CLASS
    6. ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS BASED ON MECHANISM OF ACTION
    6.1 PHASE 3 CLINICAL TRIALS ANALYTICS BASED ON MECHANISM OF ACTION
    6.2 PHASE 2 CLINICAL TRIALS ANALYTICS BASED ON MECHANISM OF ACTION
    6.3 PHASE 1 CLINICAL TRIALS ANALYTICS BASED ON MECHANISM OF ACTION
    7. ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY PHASE
    7.1 ONGOING CLINICAL TRIALS BY PHASE
    7.2 COMPLETED CLINICAL TRIALS BY PHASE
    7.3 UPCOMING CLINICAL TRIALS BY PHASE (NOT YET RECRUITING)
    8. ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY REGION
    9. ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY TRIAL STATUS (INCLUDING EXPANDED ACCESS)
    10. ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY INTERVENTION
    11. ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY TYPE
    12. ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY ENDPOINT STATUS
    13. ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS AND AVERAGE ENROLLMENT BY COUNTRY
    13.1 ANALYTICS BY TOP 5 CLINICAL TRIAL SITES
    13.1.1 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN THE US
    13.1.2 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN GERMANY
    13.1.3 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN JAPAN
    13.1.4 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN FRANCE
    13.1.5 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN SPAIN
    13.2 ANALYTICS BY EMERGING CLINICAL TRIAL SITES
    13.2.1 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN CHINA
    13.2.2 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN INDIA
    13.2.3 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN RUSSIA
    13.2.4 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN AUSTRALIA
    13.2.5 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN BRAZIL
    13.2.6 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN CHILE
    13.2.7 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN AFRICA
    13.2.8 CLINICAL TRIAL ANALYTICS BY PHASE AND TRIAL STATUS IN MIDDLE EAST
    14. SUBJECTS RECRUITED OVER A PERIOD OF TIME
    15. ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY SPONSOR TYPE
    15.1. TOP COMPANIES PARTICIPATING IN ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS
    16. MAJOR DRUGS UNDERGOING TRIALS
    17. RECENT ADVANCEMENTS IN ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS
    18. ABBREVIATIONS
    LIST OF TABLES:
    TABLE 01: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS TO BE COMPLETED IN 5 YEARS
    TABLE 02: BIOMARKERS OR TARGET RECEPTOR BASED CLINICAL TRIALS ANALYTICS
    TABLE 03: BIOMARKERS OR TARGET RECEPTOR BASED CLINICAL TRIALS ANALYTICS, PHASE 3 HSD
    TABLE 04: BIOMARKERS OR TARGET RECEPTOR BASED CLINICAL TRIALS ANALYTICS, PHASE 2 HSD
    TABLE 05: BIOMARKERS OR TARGET RECEPTOR BASED CLINICAL TRIALS ANALYTICS, PHASE 1 HSD
    TABLE 06: DRUG CLASS BASED ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS
    TABLE 07: DRUG CLASS BASED ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS, PHASE 1
    TABLE 08: DRUG CLASS BASED ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS, PHASE 2
    TABLE 09: DRUG CLASS BASED ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS, PHASE 3
    TABLE 10: MECHANISM OF ACTION BASED ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS
    TABLE 11: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS BASED ON HSD
    TABLE 12: ONGOING CLINICAL TRIALS ANALYTICS BY HSD
    TABLE 13: COMPLETED CLINICAL TRIALS ANALYTICS BY HSD
    TABLE 14: UPCOMING CLINICAL TRIALS ANALYTICS BY HSD
    TABLE 15: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY REGION
    TABLE 16: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY TRIAL STATUS
    TABLE 17: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY TYPE
    TABLE 18: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS, TOP 5 CLINICAL TRIAL SITES
    TABLE 19: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS IN THE US, PHASE AND TRIAL STATUS
    TABLE 20: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS IN GERMANY, PHASE AND TRIAL STATUS
    TABLE 21: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS IN JAPAN, PHASE AND TRIAL STATUS
    TABLE 22: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS IN FRANCE, PHASE AND TRIAL STATUS
    TABLE 23: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS IN SPAIN, PHASE AND TRIAL STATUS
    TABLE 24: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS, EMERGING CLINICAL TRIAL SITES
    TABLE 25: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS IN CHINA, PHASE AND TRIAL STATUS
    TABLE 26: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS IN INDIA, PHASE AND TRIAL STATUS
    TABLE 27: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS IN RUSSIA, PHASE AND TRIAL STATUS
    TABLE 28: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS IN AUSTRALIA, PHASE AND TRIAL STATUS
    TABLE 29: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS IN BRAZIL, PHASE AND TRIAL STATUS
    TABLE 30: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS IN CHILE, PHASE AND TRIAL STATUS
    TABLE 31: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS IN AFRICA, PHASE AND TRIAL STATUS
    TABLE 32: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS IN MIDDLE EAST, PHASE AND TRIAL STATUS
    TABLE 33: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY SPONSOR TYPE
    TABLE 34: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS, TOP COMPANIES
    TABLE 35: ANALYTICS OF THE MAJOR DRUGS BY HIGHEST STAGE OF DEVELOPMENT
    LIST OF FIGURES:
    FIGURE 01: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS, BIOMARKERS OR TARGET RECEPTOR BASED SCENARIO
    FIGURE 02: BIOMARKERS OR TARGET RECEPTOR SCENARIO, PHASE 3 CLINICAL TRIALS ANALYTICS
    FIGURE 03: BIOMARKERS OR TARGET RECEPTOR SCENARIO, PHASE 2 CLINICAL TRIALS ANALYTICS
    FIGURE 04: BIOMARKERS OR TARGET RECEPTOR SCENARIO, PHASE 1 CLINICAL TRIALS ANALYTICS
    FIGURE 05: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS BY DRUG CLASS
    FIGURE 06: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS, PHASE 3 HSD
    FIGURE 07: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS, PHASE 2 HSD
    FIGURE 08: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS, PHASE 1 HSD
    FIGURE 09: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS ANALYTICS BY MECHANISM OF ACTION
    FIGURE 10: CLINICAL TRIAL ANALYTICS, HSD SPLIT-UP
    FIGURE 11: ONGOING CLINICAL TRIALS BY PHASE
    FIGURE 12: COMPLETED CLINICAL TRIALS BY PHASE
    FIGURE 13: UPCOMING CLINICAL TRIALS BY PHASE
    FIGURE 14: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY REGION
    FIGURE 15: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY TRIAL STATUS
    FIGURE 16: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY TYPE
    FIGURE 17: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS BY ENDPOINT STATUS
    FIGURE 18: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIALS AND AVERAGE ENROLLMENT BY COUNTRY
    FIGURE 19: CLINICAL TRIAL ANALYTICS BY TOP 5 CLINICAL TRIAL SITES
    FIGURE 20: CLINICAL TRIAL ANALYTICS BY EMERGING CLINICAL TRIAL SITES
    FIGURE 21: ALPHA- ANTITRYPSIN DEFICIENCY CLINICAL TRIAL ANALYTICS, SPLIT BY SPONSOR TYPE

Pricing

Individual Pricing $1000

Corporate Pricing $1000

Enterprise Pricing $1000

(We are offering all the above license types for a single price!!)